JP2014504297A5 - - Google Patents

Download PDF

Info

Publication number
JP2014504297A5
JP2014504297A5 JP2013545118A JP2013545118A JP2014504297A5 JP 2014504297 A5 JP2014504297 A5 JP 2014504297A5 JP 2013545118 A JP2013545118 A JP 2013545118A JP 2013545118 A JP2013545118 A JP 2013545118A JP 2014504297 A5 JP2014504297 A5 JP 2014504297A5
Authority
JP
Japan
Prior art keywords
seq
oprf
fusion protein
cys27
cys18
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013545118A
Other languages
English (en)
Japanese (ja)
Other versions
JP5893640B2 (ja
JP2014504297A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/054127 external-priority patent/WO2012084272A1/en
Publication of JP2014504297A publication Critical patent/JP2014504297A/ja
Publication of JP2014504297A5 publication Critical patent/JP2014504297A5/ja
Application granted granted Critical
Publication of JP5893640B2 publication Critical patent/JP5893640B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013545118A 2010-12-23 2011-03-18 Oprf/i試薬と入院および他の患者におけるその利用 Expired - Fee Related JP5893640B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201061426760P 2010-12-23 2010-12-23
US61/426,760 2010-12-23
PCT/EP2011/054127 WO2012084272A1 (en) 2010-12-23 2011-03-18 Oprf/i agents and their use in hospitalized and other patients

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016032315A Division JP2016147867A (ja) 2010-12-23 2016-02-23 Oprf/i試薬と入院および他の患者におけるその利用

Publications (3)

Publication Number Publication Date
JP2014504297A JP2014504297A (ja) 2014-02-20
JP2014504297A5 true JP2014504297A5 (enExample) 2014-04-17
JP5893640B2 JP5893640B2 (ja) 2016-03-23

Family

ID=44210049

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013545118A Expired - Fee Related JP5893640B2 (ja) 2010-12-23 2011-03-18 Oprf/i試薬と入院および他の患者におけるその利用
JP2016032315A Pending JP2016147867A (ja) 2010-12-23 2016-02-23 Oprf/i試薬と入院および他の患者におけるその利用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016032315A Pending JP2016147867A (ja) 2010-12-23 2016-02-23 Oprf/i試薬と入院および他の患者におけるその利用

Country Status (11)

Country Link
US (1) US20130266575A1 (enExample)
EP (1) EP2655402A1 (enExample)
JP (2) JP5893640B2 (enExample)
KR (1) KR20130133212A (enExample)
CN (1) CN103270047A (enExample)
AU (1) AU2011348396A1 (enExample)
BR (1) BR112013016254A2 (enExample)
CA (1) CA2822684A1 (enExample)
MX (1) MX2013007146A (enExample)
WO (1) WO2012084272A1 (enExample)
ZA (1) ZA201304235B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9987344B2 (en) 2012-11-30 2018-06-05 Glaxosmithkline Biologicals Sa Pseudomonas antigens and antigen combinations
CN103983793A (zh) * 2014-05-29 2014-08-13 上海理工大学 一种含丽春红的蛋白质芯片点样缓冲液及其制备方法
EP3185897A4 (en) * 2014-08-29 2018-05-02 Sorrento Therapeutics, Inc. Antibody therapeutics that bind oprf and opri
CN107922482A (zh) 2015-05-01 2018-04-17 英伊布里克斯有限合伙公司 Iii型分泌系统靶向分子
WO2016193402A1 (en) 2015-06-03 2016-12-08 Valneva Austria Gmbh Pseudomonas vaccine
CN114106178A (zh) 2015-07-16 2022-03-01 印希比股份有限公司 多价和多特异性结合dr5的融合蛋白
FR3099160B1 (fr) * 2019-07-23 2022-05-06 Univ Grenoble Alpes Anticorps dirigé contre la protéine oprf depseudomonas aeruginosa, son utilisation en tant que médicament et composition pharmaceutique le contenant
CN117222740A (zh) * 2022-06-07 2023-12-12 南方科技大学 编码PcrV和/或OprF-I蛋白的mRNA疫苗
CN116251178A (zh) * 2023-03-28 2023-06-13 吉林农业大学 一种铜绿假单胞菌疫苗及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5494672A (en) * 1989-04-28 1996-02-27 S.P.I. Synthetic Peptides Incorporated Pseudomonas peptide composition and method
JP4157160B2 (ja) 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド 改変抗体可変領域の調製のための方法
EP0717106B1 (en) * 1994-12-16 2000-03-15 Chiron Behring Gmbh & Co. Immunogenic hybrid protein OprF-Oprl derived from Pseudomonas aeruginosa membrane proteins
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ,インコーポレイティド 人工抗体ポリペプチド
US20040197341A1 (en) * 2001-09-03 2004-10-07 Jean-Claude Pechere Therapeutic process for p. aeruginosa infections using macrolide antibiotics
AU2002340683C1 (en) * 2001-11-13 2009-11-12 Id Biomedical Corporation Of Quebec Polypeptides of pseudomonas aeruginosa
KR101399678B1 (ko) * 2003-01-15 2014-05-27 추가이 세이야쿠 가부시키가이샤 이량체화 펩티드
EP1623229A2 (en) 2003-05-15 2006-02-08 Cytos Biotechnology AG Selection of b cells with specificity of interest: method of preparation and use
GB0410958D0 (en) * 2004-05-15 2004-06-16 Haptogen Ltd Methods for reducing biofilm formation in infectious bacteria
CN101076342A (zh) * 2004-12-17 2007-11-21 维纳斯药业有限公司 用于对治疗感染提供总解决方案的抗生素组合
EP1921142A1 (en) 2006-11-07 2008-05-14 Cytos Biotechnology AG Selection of human monoclonal antibodies by eukaryotic cell display
US9987344B2 (en) * 2012-11-30 2018-06-05 Glaxosmithkline Biologicals Sa Pseudomonas antigens and antigen combinations

Similar Documents

Publication Publication Date Title
HRP20200871T1 (hr) Izmjenjeni rsv f proteini i postupci njihove uporabe
JP2018537087A5 (enExample)
JP2014530010A5 (enExample)
JP2009268467A5 (enExample)
JP2008529558A5 (enExample)
JP2013517783A5 (enExample)
JP2018520997A5 (enExample)
JP2008530245A5 (enExample)
JP2017532966A5 (enExample)
WO2010074575A3 (en) Recombinant classical swine fever virus (csfv) comprising a modified e2 protein and methods for generating said recombinant csfv.
JP2018033454A5 (enExample)
JP2012532601A5 (enExample)
WO2009024327A3 (en) New proteins for use in human and animal staphylococcus infections
HRP20161608T1 (hr) Modificirani tuberkulozni antigeni
JP2017048194A5 (enExample)
JP2014000092A5 (enExample)
JP2016509011A5 (enExample)
DE502007006746D1 (de) Rsv f-protein und seine verwendung
NZ702145A (en) Bluetongue virus recombinant vaccines and uses thereof
JP2011530309A5 (enExample)
JP2012516140A5 (enExample)
JP2011528222A5 (enExample)
NZ735684A (en) Materials and methods for respiratory disease control in canines
JP2013502225A5 (enExample)
JP2013523718A5 (enExample)